LifeCycle Pharma and Sciele Pharma Announce FDA Approval of New Formulation of Fenofibrate in 120 mg. and 40 mg. Dosage Strengths

    Sciele Pharma Expects U.S. Market Launch by the End of 2007

    Summary: LifeCycle Pharma and Sciele Pharma announce FDA approval of
    fenofibrate in 120 mg. and 40 mg. dosage strengths. Sciele Pharma expects
    U.S. market launch by the end of 2007.

    HORSHOLM, Denmark and ATLANTA, Aug. 13 /CNW/ -- LifeCycle Pharma A/S
(OMX: LCP) and Sciele Pharma, Inc. (Nasdaq:   SCRX) today announced that
LifeCycle Pharma has received U.S. Food and Drug Administration (FDA) approval
for LifeCycle Pharma's novel formulation of fenofibrate in 120-milligram and
40-milligram dosage strengths for the treatment of hyperlipidemia and
hypertriglyceridemia. This fenofibrate utilizes LifeCycle Pharma's Meltdose(R)
technology which is designed to provide enhanced absorption and greater
    Under the terms of the agreement with Sciele, LifeCycle Pharma has
already received an up-front payment of $5 million, and will receive a further
$4 million milestone payment now that this fenofibrate product has received
FDA approval.  LifeCycle Pharma will also receive milestone payments of up to
$8 million when certain sales targets are met, and tiered royalty payments on
product sales.  The receipt of $4 million in approval milestone does not
change LifeCycle's financial expectations for 2007.
    This fenofibrate product will have the lowest dosage strengths of
fenofibrate available for patients and will be marketed in the United States
by Sciele Pharma's Primary Care sales force by the end of 2007.  Sciele Pharma
currently has approximately 450 Primary Care sales representatives.
    "We are pleased to receive FDA approval for our first product in the
United States," said Dr. Flemming Ornskov, Chief Executive Officer of
LifeCycle Pharma. "The near-term launch of this product marks a significant
step forward for our business model.  Sciele has a proven track record in the
cardiovascular market with its Primary Care sales force, and we are excited
about our collaboration with them."
    Patrick Fourteau, Chief Executive Officer of Sciele, said, "We are
enthusiastic about introducing LifeCycle Pharma's fenofibrate in 120-milligram
and 40-milligram dosage strengths. This fenofibrate, along with our current
Triglide product line, will enable us to increase our share of the fenofibrate
market by broadening our offerings in this fast-growing area of the
cardiovascular market."
    According to the American Heart Association (AHA), over 140 million
American adults have excessive total blood cholesterol values. Fenofibrate has
proven to be very effective at lowering triglyceride concentrations and
increasing High Density Lipoprotein HDL (good cholesterol). In addition, it
has a superior side effect profile compared with alternative drugs.  Sales of
fenofibrate have increased significantly in the last few years, and in 2006,
fenofibrate sales totaled $1.7 billion worldwide, an increase of 16% over
2005. In the US alone, fenofibrate sales totaled $1.3 billion in 2006 (source:

    For further information please contact:
    LifeCycle Pharma A/S
    Flemming Ornskov
    President and CEO
    DK Tel. +45 24 20 03 68
    US Tel. +1 917 288 6446

    Michael Wolff Jensen
    Executive Vice President and CFO
    Tel. +45 40 74 62 44
    About LifeCycle Pharma A/S:
    LifeCycle Pharma, headquartered in Horsholm, Denmark, is an emerging
pharmaceutical company with a broad and late stage product pipeline in
therapeutic areas of cholesterol management, hypertension, organ transplant
and autoimmune diseases. LifeCycle Pharma's proprietary technology platform,
MeltDose(R) technology, offers lower dosing, reduced side effects and improved
safety and patient compliance, as well as reduced product development time and
development costs. LifeCycle Pharma is listed on the OMX Nordic Exchange under
the trading symbol (LCP). Please visit for further
information about LifeCycle Pharma A/S.
    About Sciele Pharma, Inc.:
    Sciele Pharma, Inc., headquartered in Atlanta Georgia is a pharmaceutical
company specializing in sales, marketing and development of branded
prescription products focused on Cardiovascular/Diabetes, Women's Health and
Pediatrics. The Company's Cardiovascular/Diabetes products treat patients with
high cholesterol, hypertension, high triglycerides, unstable angina and Type 2
diabetes; its Women's Health products are designed to improve the health and
well-being of women and mothers and their babies; and its Pediatrics products
treat allergies, asthma, coughs and colds, and Attention Deficit/Hyperactivity
Disorder (ADHD). Founded in 1992 and headquartered in Atlanta, Georgia, Sciele
Pharma employs more than 900 people. The Company's success is based on placing
the needs of patients first, improving health and quality of life, and
implementing its business platform - an Entrepreneurial Spirit, Innovation,
Speed of Execution, Simplicity, and Teamwork.  For more information, visit:

For further information:

For further information: Flemming Ornskov President and CEO DK, +45 24
20  03 68, or US, +1 917 288 6446, or Michael Wolff Jensen, Executive Vice
President  and CFO, +45 40 74 62 44, both of LifeCycle Pharma A/S Web Site:        

Organization Profile


More on this organization


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890